US biopharmaceutical company Vericel Corp (Nasdaq: VCEL) saw its shares rocket by as much as 92% on Thursday after announcing positive results in its Phase IIb trial of ixmyelocel-T.
The study looked at the impact of the drug on patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Vericel, which is a leading developer of patient-specific expanded cellular therapies of the treatment of severe diseases and conditions, found the trial met its primary goal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze